Kellman Pharmaceutical Services is now working with GlobeImmune as a Functional Service Provider (FSP). GlobeImmune Inc is a private company developing therapeutic vaccines called Tarmogens for the treatment of cancer and infectious diseases. As a FSP, KPS is providing more efficient data management and cost containment expertise through more efficient data monitoring and reporting.
“We were brought in to provide a more efficient monitoring alternative and are succeeding,” explains KPS President David Kelly. “We look forward to expanding our relationship and scope of services for the company in the future.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.